^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non Small Cell Lung Cancer
    Drug:deulorlatinib (TGRX-326) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

    Excerpt:
    ...- Diagnosis of ALK-positive or ROS1-positive advanced NSCLC by histopathology or cytology in a Grade-A tertiary hospital or central laboratory....
    Trial ID:
    NCT05441956
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.

    Published date:
    05/25/2023
    Excerpt:
    TGRX-326 was well tolerated in pts with advanced ALK+NSCLC and showed promising clinical antitumor activity…
    DOI:
    10.1200/JCO.2023.41.16_suppl.9113
    Trial ID:
    NCT05441956